Breaking News Instant updates and real-time market news.

PRGO

Perrigo

$48.42

1.41 (3.00%)

, BHC

Bausch Health

$25.33

0.235 (0.94%)

09:28
02/13/19
02/13
09:28
02/13/19
09:28

Perrigo reaches settlement on patent ligitation case for generic Jublia solution

Perrigo (PRGO) has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for the generic equivalent to Jublia Topical Solution 10% brought by Bausch Health's (BHC) Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., and Dow Pharmaceuticals Sciences, and Kaken Pharmaceuticals. Terms of the settlement are confidential.

PRGO

Perrigo

$48.42

1.41 (3.00%)

BHC

Bausch Health

$25.33

0.235 (0.94%)

DWDP

DowDuPont

$53.35

1.35 (2.60%)

  • 15

    Feb

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

PRGO Perrigo
$48.42

1.41 (3.00%)

02/01/19
WELS
02/01/19
NO CHANGE
Target $46
WELS
Market Perform
Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo
Wells Fargo analyst David Maris noted that GlaxoSmithKline (GSK) launched an authorized generic of Ventolin on January 15 and he has now learned that Teva (TEVA) may have "surprisingly launched" an authorized generic of ProAir in response to the generic Ventolin pressure prior to Perrigo's (PRGO) approval. Pricing pressure from generic Ventolin, in addition to the launch of an authorized generic well ahead of Perrigo's own generic ProAir launch, seem to have significantly diminished Perrigo's generic ProAir opportunity, Maris tells investors. He keeps a Market Perform rating and $46 price target on Perrigo shares.
12/21/18
CANT
12/21/18
NO CHANGE
Target $107
CANT
Overweight
Cantor Fitzgerald says don't read too much into Perrigo tax headlines
Cantor Fitzgerald analyst Louise Chen tells investors not to read too much into the headlines from Perrigo last night regarding an Irish corporation tax liability. In a research note titled "Bah-Humbug, Don't Let Headlines Ruin The Holidays," Chen says it is "unclear that there is much of a case here." The analyst keeps an Overweight rating on Perrigo with a $107 price target.
11/28/18
11/28/18
NO CHANGE

Perrigo reaches settlement in Sernivo patent litigation case
Perrigo has settled its Hatch-Waxman litigation relating to Sernivo Spray brought by Promius Pharma. Terms of the settlement are confidential. Sernivo Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older. Annual market sales for the 12 months ending September 2018 were approximately $13M.
11/14/18
WELS
11/14/18
NO CHANGE
Target $64
WELS
Market Perform
Perrigo price target lowered to $64 form $77 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Perrigo to $64 from $77 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
BHC Bausch Health
$25.33

0.235 (0.94%)

01/02/19
PIPR
01/02/19
UPGRADE
Target $27
PIPR
Overweight
Bausch Health upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Bausch Health Companies to Overweight from Neutral and raised his price target for the shares to $27 from $22. The company formerly known as Valeant Pharmaceuticals closed Monday down 32c to $18.47. The analyst says that while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." Management has positioned Bausch not only for longer-term EBITDA stability, but potentially "meaningful" growth, Amsellem tells investors in a research note. While the company is still highly levered, a favorable maturity schedule gives it "ample breathing room," and strong visibility into EBITDA stability/growth should enable the company to "chip away significantly at debt levels in the coming years," says the analyst. He thinks Bausch Health's valuation is positioned for multiple expansion over time.
01/02/19
01/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bausch Health (BHC) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." 2. Crocs (CROX) and Shoe Carnival (SCVL) were upgraded to Positive from Neutral at Susquehanna. 3. Stryker (SYK) upgraded to Outperform from In Line at Evercore ISI. 4. CBS (CBS) upgraded to Overweight from Equal Weight at Stephens with analyst Kyle Evans saying he believes investor sentiment is poised to improve on the name in 2019 and that the company can continue to post solid results driven by underlying unit growth and stronger pricing. 5. Sirius XM (SIRI) upgraded to Overweight from Neutral at JPMorgan with analyst Sebastiano Petti saying Sirius XM shares are attractively following the 25% pullback from the 2018 highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
PIPR
01/10/19
NO CHANGE
Target $27
PIPR
Overweight
Piper sees Bausch Health as 'stand out' after management meeting
Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Bausch Health Companies with a $27 price target after meeting with management. The analyst says commentary from the company reinforced his view that Bausch will continue to "stand out among the broader group of highly-levered specialty pharma names." Management has high visibility into not only longer-term EBITDA stability but meaningful long-term growth, Amsellem tells investors in a research note. Significant growth from the gastroenterology franchise along with modest growth from the dermatology and eye care segments should translate into a long-term annual EBITDA growth at least in the mid-single digits, says the analyst.
01/02/19
PIPR
01/02/19
NO CHANGE
PIPR
Piper calls Horizon top 2019 growth idea in Specialty Pharmaceuticals
Piper Jaffray analyst David Amsellem calls Horizon Pharma (HZNP) his top "growth oriented/GARP idea" for 2019. The company offers high asset quality, visibility into significant longer-term EBITDA growth, and manageable debt levels that enable significant business development flexibility, Amsellem tells investors in a research note. He believes the Specialty Pharmaceuticals group is well positioned to perform more in-line with the broader therapeutics and overall healthcare spaces in 2019, or "certainly better than what we have seen in recent years." The analyst names Bausch Health (BHC), a stock he upgraded this morning to Overweight, his top "de-leveraging/defensive pick" for 2019. Further, Amsellem's top "development-stage picks" for 2019 are Cara Therapeutics (CARA) and Revance Therapeutics (RVNC).
DWDP DowDuPont
$53.35

1.35 (2.60%)

02/05/19
ARGS
02/05/19
NO CHANGE
Target $70
ARGS
Buy
DowDuPont price target lowered to $70 from $81 at Argus
Argus analyst Bill Selesky lowered his price target on DowDuPont to $70 after its Q4 earnings came in below his forecast, also lowering his FY19 EPS view to $4.18 from $4.93 after the result and the company's FY19 guidance. The analyst notes that while the company registered an improvement in operating earnings from last year from price and volume gains, the benefits were offset by negative currency translation effects. Selesky keeps his Buy rating on DowDuPont shares citing its attractive valuation of 1.3-times trailing price to book, which is below its historical range of 1.4- to 1.6-times.
02/06/19
COWN
02/06/19
DOWNGRADE
COWN
Market Perform
DowDuPont downgraded to Market Perform from Outperform at Cowen
02/06/19
COWN
02/06/19
DOWNGRADE
Target $59
COWN
Market Perform
DowDuPont downgraded to Market Perform on industry headwinds at Cowen
As reported previously, Cowen analyst Charles Neivert downgraded DowDuPont to Market Perform from Outperform. The analyst said recent subtle changes in industry fundamentals and the macro outlook have made him more cautious. He believes margin pressure will be present throughout most of 2019 based on headwinds from feedstocks, capacity, and a weakening macro versus consensus. Neivert lowered his price target to $59 from $78 on DowDuPont shares.
02/04/19
RHCO
02/04/19
NO CHANGE
Target $57
RHCO
Hold
DowDuPont price target lowered to $57 from $61 at SunTrust
SunTrust analyst James Sheehan lowered his price target on DowDuPont to $57 and kept his Hold rating after its in-line Q4 earnings and below-consensus revenue along with anticipated Q1 EBITDA decline in its Materials Science and Specialty Products segments. The analyst sees "weak outlook driven by expectations of multiple headwinds" continuing from Q4 to Q1 that include "inventory destocking, soft demand in China/Europe, weak auto and electronics end markets, commodity spread compression and FX", warning that any upside on DowDuPont shares is likely to be limited until investors see destocking completed.

TODAY'S FREE FLY STORIES

CBLK

Carbon Black

$16.50

0.16 (0.98%)

16:12
02/20/19
02/20
16:12
02/20/19
16:12
Earnings
Carbon Black sees FY19 EPS (64c)-(61c), consensus (70c) »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 13

    Mar

LOPE

Grand Canyon

$97.09

0.14 (0.14%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Earnings
Grand Canyon sees Q1 EPS $1.49, consensus $1.40 »

Sees Q1 revenue $195.5M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MANT

ManTech

$58.49

0.58 (1.00%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Hot Stocks
ManTech increases quarterly dividend to 27c from 25c »

The company has increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ROG

Rogers Corporation

$136.53

1.23 (0.91%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Hot Stocks
Breaking Hot Stocks news story on Rogers Corporation »

Rogers Corporation sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 07

    Mar

XPER

Xperi

$23.18

0.36 (1.58%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Earnings
Breaking Earnings news story on Xperi »

Xperi sees Q1 billings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Mar

  • 28

    Mar

CBLK

Carbon Black

$16.50

0.16 (0.98%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Earnings
Carbon Black sees Q1 EPS (23c)-(22c), consensus (21c) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 13

    Mar

ROG

Rogers Corporation

$136.53

1.23 (0.91%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Earnings
Rogers Corporation sees Q1 adjusted EPS $1.25-$1.40, consensus $1.42 »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 07

    Mar

XPER

Xperi

$23.18

0.36 (1.58%)

16:11
02/20/19
02/20
16:11
02/20/19
16:11
Earnings
Breaking Earnings news story on Xperi »

Xperi reports Q4 billings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Mar

  • 28

    Mar

AMSWA

American Software

$11.61

0.09 (0.78%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Earnings
American Software reports Q3 adjusted EPS 10c, one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ROG

Rogers Corporation

$136.52

1.22 (0.90%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Earnings
Rogers Corporation reports Q4 adjusted EPS $1.67, consensus $1.27 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 07

    Mar

CBLK

Carbon Black

$16.54

0.2 (1.22%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Earnings
Carbon Black reports Q4 EPS (20c), consensus (24c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 13

    Mar

LOPE

Grand Canyon

$97.03

0.08 (0.08%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Earnings
Grand Canyon reports Q4 EPS $1.56, consensus $1.42 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MANT

ManTech

$58.49

0.58 (1.00%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Earnings
ManTech sees FY19 EPS $2.15-$2.28, consensus $2.32 »

Sees FY19 revenue $2.05B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GDDY

GoDaddy

$72.30

-0.39 (-0.54%)

16:10
02/20/19
02/20
16:10
02/20/19
16:10
Hot Stocks
Breaking Hot Stocks news story on GoDaddy »

GoDaddy drops 2% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

GDOT

Green Dot

$74.60

-0.14 (-0.19%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Green Dot sees FY19 adjusted EPS $3.59-$3.67, consensus $3.62 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITC

Site Centers

$12.98

-0.41 (-3.06%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Site Centers sees FY19 FFO $1.13-$1.18, consensus $1.16 »

Backs FY19 Same-store NOI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

A

Agilent

$78.56

1.08 (1.39%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Agilent sees Q2 EPS 70c-72c, consensus 72c »

Sees Q2 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

GDDY

GoDaddy

$72.29

-0.4 (-0.55%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Breaking Earnings news story on GoDaddy »

GoDaddy sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

VIPS

Vipshop

$7.31

0.36 (5.18%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Vipshop sees Q1 revenue growth 0%-5%, consensus $3.2B »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GDOT

Green Dot

$74.68

-0.06 (-0.08%)

16:09
02/20/19
02/20
16:09
02/20/19
16:09
Earnings
Green Dot reports Q4 adjusted EPS 56c, consensus 50c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MANT

ManTech

$58.49

0.58 (1.00%)

16:08
02/20/19
02/20
16:08
02/20/19
16:08
Earnings
ManTech reports Q4 EPS 50c, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

SREV

ServiceSource

$1.15

-0.03 (-2.54%)

16:08
02/20/19
02/20
16:08
02/20/19
16:08
Earnings
ServiceSource reports Q4 FFO 31c, consensus 30c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Mar

GDDY

GoDaddy

$72.29

-0.4 (-0.55%)

16:08
02/20/19
02/20
16:08
02/20/19
16:08
Earnings
GoDaddy sees 2019 revenue $2.97B-$3.0B, consensus $2.99B »

For the full year 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

A

Agilent

$78.58

1.1 (1.42%)

16:08
02/20/19
02/20
16:08
02/20/19
16:08
Earnings
Agilent raises FY19 EPS view to $3.03-$3.07 from $3.00-$3.05, consensus $3.05 »

Raises FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

VIPS

Vipshop

$7.31

0.36 (5.18%)

16:07
02/20/19
02/20
16:07
02/20/19
16:07
Earnings
Vipshop reports Q4 adjusted EPS 19c, consensus 18c »

Reports Q4 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.